Angelica Oropeza, | |
1200 Wilshire Blvd, Los Angeles, CA 90017-1908 | |
(213) 481-7464 | |
(213) 481-7147 |
Full Name | Angelica Oropeza |
---|---|
Gender | Female |
Speciality | Case Manager/care Coordinator |
Location | 1200 Wilshire Blvd, Los Angeles, California |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1003004243 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
101Y00000X | Counselor | (* (Not Available)) | Secondary |
171M00000X | Case Manager/care Coordinator | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Angelica Oropeza, 1200 Wilshire Blvd, Los Angeles, CA 90017-1908 Ph: (213) 481-7464 | Angelica Oropeza, 1200 Wilshire Blvd, Los Angeles, CA 90017-1908 Ph: (213) 481-7464 |
News Archive
Promising clinical trial results presented at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show activity of the investigational anti-cancer agent ONT-380 against HER2+ breast cancer, in one case specifically against brain metastases and in another case in overall survival of heavily pretreated HER2+ breast cancer patients.
Sexual activity declines in the year after heart attack for patients who don't get instructions from their doctors about when it's safe to resume sex, researchers reported at the American Heart Association's 11th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke.
"The boundary between religious belief and the practice of psychiatry is becoming increasingly porous," say the editors in the Preface to Religion and Psychiatry: Beyond Boundaries. "No longer can psychiatrists in a multi-faith, multi-cultural globalized world hide behind the dismissal of religious belief as pathological, or behind a biomedical scientism, as they are more frequently confronted by distressed patients for whom religious belief may determine their choice of symptoms and their compliance with treatment."
Researchers at Juntendo University report in the journal Leukemia how mutants of the protein calreticulin lead to molecular mechanisms triggering myeloproliferative neoplasms, which can cause cancer. The findings may lead to the development of novel therapies for certain types of blood cancer.
› Verified 2 days ago